[Direct Report Network Beijing November 16th] (Securities Daily) "Last year, Kang Enbei has carried out a strategic adjustment, industry positioning, clear focus on pharmaceuticals, professional pharmaceuticals!" Kang Enbei chairman Hu Jiqiang said in the industry Strategically, the modern Chinese medicine and botanical medicine business will be regarded as the basic industry; in the chemical medicine, a few of the first-come-first treatment areas will be focused; in the bio-pharmaceutical field, the investment and business cooperation will be strategically involved.

 

In order to achieve this strategic goal, last year, Kang Enbei proposed and began to implement the "big brand large variety project." There are more than 300 traditional Chinese medicine products in Kang Enbei's existing products, and there are nearly 50 chances to expand. Hu Jiqiang is pondering what kind of tactics and management to make these varieties bigger.

 

Cooperating with the “big brand and large variety project”, Kang Enbei has adjusted the organizational structure and set up multiple independent operation teams according to the big brand and large variety projects. Each team focuses on 2, 3 target varieties, each team It is a profit center.

 

Hu Jiqiang expects Kang Enbei to become a leader in the domestic Chinese medicine pharmaceutical industry in the next five years.

 

Hu Jiqiang said that the company continued to focus on large-scale brand and large-scale projects this year to promote high-quality development. Endogenous growth has achieved positive results on the basis of last year. From January to September, the brand and products included in the big brand and large-scale engineering projects realized a total sales income of 3.941 billion yuan, a year-on-year increase of 52.25%. Among them, "Kangbeibei" brand enteritis series products, "Jindi" brand compound Houttuynia cordata The sales revenue of the mixture and “Jinkang Suili” brand acetylcysteine ​​effervescent tablets reached 610 million yuan, 260 million yuan and 12,700 yuan respectively, up 39.87%, 143.11% and 47.12% respectively. Lean and Tamsulosin and other series of products, "Zhen Shi Ming" brand eye drops and eye health products, "Kang Enbei" brand Yuxiang Tongxin pill and other brands and products sales revenue increased by about 30%. At present, the company has a variety of sales of more than 1 billion yuan, and is expected to produce the second one next year.

 

Kang Enbei will continue to promote large-scale brand and large-scale projects, forming professional leading brand advantages in many sub-sectors such as cardiovascular and cerebrovascular, respiratory, urinary, gastrointestinal, cold, pneumoconiosis, and plans to form 3~5 within 3 years. A large brand of products with a total value of more than 1 billion yuan has laid a solid foundation for the company's 10-year goal of 10 billion yuan.